MiR-486 As an Unfavorable Prognostic Biomarker for Patients with Non-small Cell Lung Cancer

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Feb 4

PMID 35117163

Authors

Zhao-Jia Gao

Wei-Dong Yuan

Jun-Qiang Yuan

Kai Yuan

Yong Wang

Affiliations

Soon will be listed here.

Abstract

Background: Non-small cell lung cancer (NSCLC) is the most common malignant tumor in China. miR-486 was found to be associated with many tumors. In previous study, we aimed to investigate the expression and prognostic value of miR-486 in patients with NSCLC.

Methods: In order to measure the expression of miR-486 in 140 NSCLC patients, in situ hybridization (ISH) was made. The staining of miR-486 was scored by two independent investigators. Then, the prognostic value of miR-486 was evaluated by plotting Kaplan-Meier survival curves and making multivariate analysis.

Results: miR-486 was mainly expressed in the cytoplasm of tumor cells. miR-486 expression was corrected with tumor differentiation (P=0.011) but not with any other clinicopathological characteristics. However, high expression of miR-486 was significantly correlated with shortened overall survival (OS) in NSCLC patients (P=0.001), especially in stage I patients (P=0.005). Multivariate analysis revealed that miR-486 was an independent prognostic factor in NSCLC patients (P=0.002).

Conclusions: miR-486 high expression predicts poor survival in patients with NSCLC. miR-486 could be used as an unfavorable prognostic biomarker for NSCLC patients.

Citing Articles

Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab.

Genova C, Marconi S, Chiorino G, Guana F, Ostano P, Santamaria S Clin Exp Med. 2024; 24(1):182.

PMID: 39105937 PMC: 11303437. DOI: 10.1007/s10238-024-01427-8.

References

Lin P, Yang P . Circulating miRNA signature for early diagnosis of lung cancer. EMBO Mol Med. 2011; 3(8):436-7. PMC: 3377090. DOI: 10.1002/emmm.201100155. View

Wang J, Tian X, Han R, Zhang X, Wang X, Shen H . Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene. 2013; 33(9):1181-9. PMC: 3883922. DOI: 10.1038/onc.2013.42. View

Rai K, Takigawa N, Ito S, Kashihara H, Ichihara E, Yasuda T . Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther. 2011; 10(9):1720-7. DOI: 10.1158/1535-7163.MCT-11-0220. View

Yuan K, Gao Z, Yuan W, Yuan J, Wang Y . High expression of SLC6A10P contributes to poor prognosis in lung adenocarcinoma. Int J Clin Exp Pathol. 2020; 11(2):720-726. PMC: 6958030. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F . MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011; 108(9):3713-8. PMC: 3048155. DOI: 10.1073/pnas.1100048108. View

Ambros V . The functions of animal microRNAs. Nature. 2004; 431(7006):350-5. DOI: 10.1038/nature02871. View

Cooper W, Lam D, OToole S, Minna J . Molecular biology of lung cancer. J Thorac Dis. 2013; 5 Suppl 5:S479-90. PMC: 3804875. DOI: 10.3978/j.issn.2072-1439.2013.08.03. View

Lang B, Zhao S . miR-486 functions as a tumor suppressor in esophageal cancer by targeting CDK4/BCAS2. Oncol Rep. 2017; 39(1):71-80. PMC: 5783606. DOI: 10.3892/or.2017.6064. View

10.

Li W, Wang Y, Zhang Q, Tang L, Liu X, Dai Y . MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer. PLoS One. 2015; 10(8):e0134220. PMC: 4523212. DOI: 10.1371/journal.pone.0134220. View

11.

Yang Y, Ji C, Guo S, Su X, Zhao X, Zhang S . The miR-486-5p plays a causative role in prostate cancer through negative regulation of multiple tumor suppressor pathways. Oncotarget. 2017; 8(42):72835-72846. PMC: 5641172. DOI: 10.18632/oncotarget.20427. View

12.

Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

13.

Zhao Y, Wei Q, Hu L, Chen F, Hu Z, Heist R . Polymorphisms in MicroRNAs are associated with survival in non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2014; 23(11):2503-11. PMC: 4221531. DOI: 10.1158/1055-9965.EPI-14-0389. View

14.

Sromek M, Glogowski M, Chechlinska M, Kulinczak M, Szafron L, Zakrzewska K . Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection. Cell Oncol (Dordr). 2017; 40(5):529-536. DOI: 10.1007/s13402-017-0334-8. View

15.

Gao Z, Wang Y, Yuan W, Yuan J, Yuan K . HIF-2α not HIF-1α overexpression confers poor prognosis in non-small cell lung cancer. Tumour Biol. 2017; 39(6):1010428317709637. DOI: 10.1177/1010428317709637. View

16.

Lin C, Xie L, Lu Y, Hu Z, Chang J . miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells. Int J Mol Med. 2018; 41(4):2050-2058. PMC: 5810210. DOI: 10.3892/ijmm.2018.3382. View

17.

Xu J, Cao Z, Liu W, You L, Zhou L, Wang C . Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study. Ann Surg. 2015; 263(6):1173-9. DOI: 10.1097/SLA.0000000000001345. View

18.

Song C, Chen H, Wang T, Zhang W, Ru G, Lang J . Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing. Prostate. 2015; 75(5):500-16. DOI: 10.1002/pros.22936. View

19.

Castro D, Moreira M, Gouveia A, Pozza D, de Mello R . MicroRNAs in lung cancer. Oncotarget. 2017; 8(46):81679-81685. PMC: 5655318. DOI: 10.18632/oncotarget.20955. View

20.

Zheng D, Haddadin S, Wang Y, Gu L, Perry M, Freter C . Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol. 2011; 4(6):575-86. PMC: 3160609. View